In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance…
<!-- Name:DistributionId Value:8753420 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Alector
Alector Presents Encouraging New AL001 Data from the Symptomatic FTD-GRN Cohort of…
Progranulin Levels Increase to Normal Ranges Multiple Biomarkers of Disease Showed Improvement from Baseline with AL001 Treatment, Including GFAP, a Prognostic Marker for FTD Associated…
Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference…
Company to Host Analyst and Investor Conference Call on November 12 at 4:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a…
Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical…
AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients Treatment with AL001 Slowed Clinical Progression by 47% Based on the CDR® plus NACC FTLD-SB Scale Relative to…
Alector and GSK announce global collaboration in immuno-neurology for two clinical…
Alector and GSK to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral…